⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMEA News
Biomea Fusion, Inc. Common Stock
Biomea Fusion to Participate at Upcoming Investor Conferences
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
globenewswire.com
BMEA
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
globenewswire.com
BMEA
Form 8-K
sec.gov
BMEA
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
globenewswire.com
BMEA
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
globenewswire.com
BMEA